Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-07-17 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the inspection of Lupin's manufacturing facility by the U.S. FDA. It mentions the issuance of a Form-483 with observations and the company's commitment to address them. The document references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure obligations. The document is brief (1867 characters) and does not contain any financial data, detailed reports, or management discussion. It is an announcement of an event (FDA inspection and Form-483 issuance) rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-17 English
Inspection of U.S. FDA at the Company''s Pithampur Unit-3 manufacturing facility.
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations, reporting on the U.S. FDA inspection of Lupin's manufacturing facility and the issuance of a Form-483 with observations. It is a regulatory announcement about compliance and inspection results, not a full report or financial statement. The document is short (1867 characters) and serves as a regulatory update rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-17 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations, notifying about the U.S. FDA inspection of Lupin's manufacturing facility and the issuance of a Form-483 with observations. It is a regulatory announcement about compliance and inspection results, not a financial report, earnings release, or management discussion. The document is short (1931 characters) and serves as a regulatory update rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-17 English
Inspection of U.S. FDA at the Company''s Pithampur Unit-2 manufacturing facility.
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations, reporting on the U.S. FDA inspection of Lupin's manufacturing facility and the issuance of a Form-483 with observations. It is a regulatory announcement about compliance and inspection results, not a financial report, earnings release, or management discussion. The document is short (1931 characters) and serves as a regulatory update rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-17 English
Lupin Achieves GMP Certification from TGA Australia for Dabhasa API Facility.
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lupin Limited's subsidiary has received Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA) of Australia. It is addressed to stock exchanges and regulatory bodies under SEBI regulations, indicating it is a regulatory disclosure. The content is an announcement of a certification achievement, not a financial report, management discussion, or any other detailed report type. The document length is about 5,321 characters, which is relatively short and focused on a single announcement. There is no financial data, no discussion of financial results, no voting results, no management changes, or other report types. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lupin Limited's subsidiary has received Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA) of Australia. It is addressed to stock exchanges and includes contact information and company background. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is an announcement of a certification achievement, not a financial or governance report. It is also relatively short (5321 characters) and serves as a disclosure pursuant to SEBI regulations, which fits the profile of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-07-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.